BioSight
Companies
FENNEC PHARMACEUTICALS INC. logo

FENC

NASDAQRESEARCH TRIANGLE PARK, NC
FENNEC PHARMACEUTICALS INC.

Fennec Pharmaceuticals is a commercial-stage specialty pharmaceutical company focused on oncology and rare disease, with PEDMARK (sodium thiosulfate injection), a small molecule product approved by the FDA for the prevention of cisplatin-induced ototoxicity in pediatric cancer patients. The company is engaged in patent protection and litigation defense for PEDMARK against generic competition, with market exclusivity secured through orphan drug designation and pediatric exclusivity, though facing ongoing Paragraph IV certifications challenging its patent portfolio.

Price history not yet available for FENC.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar